Interstitial Lung Disease
Jefferson Pulmonary Associates Receives Highest Recognition
Jefferson Pulmonary Associates achieves Level 3 status as a Patient-Centered Specialty Practice (PCSP) from the National Center for Quality Assurance (NCQA).
Interstitial lung disease is a term used to describe a group of conditions that cause scarring and/or inflammation in space between the air sacs of the distal lung. In most patients, inflammation and scarring gradually interfere with gas-exchange and cause slowly progressive shortness of breath, chronic dry hacking cough and decreased blood oxygen levels.
Why Choose Jefferson for Interstitial Lung Disease Treatment?
Management of patients with interstitial lung diseases is often complex and varies depending on the underlying cause. For patients referred to Jefferson, our pulmonologists work closely with a wide range of healthcare providers including thoracic surgeons, rheumatologists, nurses and respiratory therapists.
The first step for patients referred to our clinic is to undergo a comprehensive evaluation to determine the cause and the best course of treatment of interstitial lung disease.
Forms of Interstitial Lung Disease
Our physicians evaluate all forms of this lung condition including:
- Acute interstitial pneumonia (AIP or Hamman-Rich syndrome)
- Connective tissue-related lung fibrosis (scleroderma, systemic lupus erythematosis, Sjogren's, rheumatoid arthritis)
- Drug-induced lung fibrosis
- Hypersensitivity pneumonitis
- Idiopathic forms of lung fibrosis
- Langerhan's cell histiocytosis (aka Eosinophilic granuloma or Histiocytosis X)
- Occupational-related lung fibrosis (e.g. asbestosis)
- Pulmonary alveolar proteinosis (PAP)
- Radiation-induced lung fibrosis
Clinical Trials for Interstitial Lung Disease
Although our physicians follow evidence-based guidelines for all conditions, we also offer enrollment in clinical trials for those patients with conditions that have limited effective treatments.
We are currently enrolling patients with idiopathic pulmonary fibrosis in the GS-US-322-0207 study trial, a global study of a novel humanized monoclonal antibody that binds to LOXL2. This therapy aims to reduce morbidity and mortality from this serious condition.